Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming

STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai

Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity

STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast

STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, supports the new National Society of Genetic Counselors guidelines recommending exome sequencing as a first-tier test, to be prioritized over multi-gene panels for all individuals with unexplained epilepsy, and applauds the American Epilepsy Society for endorsing these guidelines. This is the first evidence-based guideline for genetic testing for individuals with unexplained epilepsy, and the implications are vast, as a significant amount of unexplained epilepsy has a genetic cause1. In many cases, identifying a molecular genetic cause of epilepsy can have implications for treatment and

-- Abnormal findings reported in 63% of infants in study, change in health management recommended in 88% of cases ---- Sema4|GeneDx contributes to latest data in the SeqFirst study being presented at the American Society of Human Genetics Annual Meeting -- STAMFORD, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced updated research showing the clear benefits of rapid whole genome sequencing (rWGS) to diagnose critically ill newborns in the neonatal intensive care unit (NICU). The findings come from the recently completed first phase of the SeqFirst study, for which Sema4|GeneDx performed the sequencing, and was conducted in partnershi

STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels. The study demonstrates that using exome or genome sequencing results in a significantly lower rate of variants of uncertain significance (VUS) compared to panel-based testing, underscoring the importance of genomic sequencing for improving diagnoses and health outcomes. It is one of more than a dozen studies Sema4|GeneDX is either presenting, or has participated in, being showcased at the American Society of Human Genetics (ASHG) Annual Meeti

Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child Neurology Society (CNS) Annual Meeting on October 13, 2022 STAMFORD, Conn., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, is presenting research today on autism spectrum disorders (ASD) at the Child Neurology Society (CNS) Annual Meeting. The research underscores the positive outcomes of exome analysis for individuals with ASD, supporting the use of a broader genetic testing approach to reach a faster diagnosis. This study of almost 19,000 individuals is one

STAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening Against Rare Diseases In All Newborns), a collaboration among premier non-profit, academic, government, and industry organizations. GUARDIAN is using whole genome sequencing (WGS) to screen 100,000 newborns for more conditions than those currently included in standard newborn screening. The goals of the study are to drive earlier diagnosis and treatment to improve the health of the babies who participate, generate evidence to support the expansion of newborn screening through genomic sequencing,

SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)

SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

Goldman downgraded Sema4 Holdings Corp from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

Jefferies downgraded Sema4 Holdings Corp from Buy to Hold and set a new price target of $2.00 from $4.00 previously

Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50

Goldman Sachs initiated coverage of Sema4 Holdings with a rating of Buy and set a new price target of $12.00

BTIG Research initiated coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $12.00

Cowen & Co. initiated coverage of Sema4 Holdings with a rating of Outperform and set a new price target of $13.00

Jefferies initiated coverage of Sema4 Holdings with a rating of Buy and set a new price target of $13.00

STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial

Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

4 - GeneDx Holdings Corp. (0001818331) (Issuer)

8-K - GeneDx Holdings Corp. (0001818331) (Filer)

144 - GeneDx Holdings Corp. (0001818331) (Subject)

10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

8-K - GeneDx Holdings Corp. (0001818331) (Filer)

S-8 - GeneDx Holdings Corp. (0001818331) (Filer)

8-K - GeneDx Holdings Corp. (0001818331) (Filer)

8-K - GeneDx Holdings Corp. (0001818331) (Filer)

8-K - GeneDx Holdings Corp. (0001818331) (Filer)

DEFA14A - GeneDx Holdings Corp. (0001818331) (Filer)

8-K - GeneDx Holdings Corp. (0001818331) (Filer)

Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity

STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast

New management team implements significant restructuring to focus on profitable growth, efficiency, and scale 19% pro forma1 volume growth vs. 2Q 2021 Sema4 to host a conference call today at 4:30 p.m. ET STAMFORD, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced a series of corporate realignments, business highlights, and financial results for the second quarter ended June 30, 2022. "We saw strong volume growth in both our reproductive health and recently acquired pediatrics and rare disease businesses, which delivered on record volumes. The underlying performance of the legacy GeneDx busi

STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the second quarter of 2022 after the market close on Monday, August 15, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Richard Miao, Interim Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the

Total revenue of $53.9 million 1,300 basis points of sequential adjusted gross margin improvement Reaffirming full year 2022 pro forma revenue target New operating model and focus on efficiencies to reduce 2022 cash burn by an estimated $50 million, extending cash runway into 2024 Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., May 12, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the first quarter ended March 31, 2022 and provided an update on key strategic and operational initiatives. "I am very pleased by our start to the yea

Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx, joins Sema4 as CEO and will serve on Board of Directors Eric Schadt, founder and former CEO of Sema4, to serve as President and Chief Research & Development Officer and to continue to serve on Board of Directors Sema4 closes $200 million private placement from leading growth and life sciences investors, including Pfizer STAMFORD, Conn., May 02, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it has completed

STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the first quarter of 2022 after the market close on Thursday, May 12, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET. Conference Call Details The conference call will begin at 4:30 p.m. ET on Thursday, May 12, 2022. Interested parties may access the live teleconference by dialing (844) 631-4065 for domestic callers or (929

37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market close on Monday, March 14, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET. Additionally, Company management will participate in two virtual investor conferences in March. Fourth Quarter and Full Year 2021 Conference Call Details The conference call will begin at 4:30 p.